CeQur®

CeQur Simplicity™

Convenient, discreet, 3-day, wearable insulin Patch for injection-free dosing

CeQur Simplicity™

FDA Cleared

Mealtime insulin is always within reach

Designed to remove the inconvenience, embarrassment, and pain of rapid insulin dosing

- **Simple to use**
- **Discreet**
- **Wearable 3-day insulin patch**
- **For injection-free mealtime dosing**

A two-button squeeze delivers 2U of rapid-acting insulin via a soft flexible cannula, enabling fast and discreet dosing in any situation.

Holds up to 200 units, compatible with U-100 rapid-acting (mealtime) insulin: Humalog® and NovoLog®.

Removing known barriers to insulin dosing may help patients achieve glycemic targets[1]

88% of patients said CeQur Simplicity helps them do a better job of following their insulin regimen[2]

1. Bergenstal R, Peyrot M, Dreon D, Aroda V, Bailey T, Brazg R, Frias J, Johnson M, Klonoff D, Kruger D, Ramtoola S, Rosenstock J, Serusclat P, Weinstock R, Naik R, Shearer D, Zraick V, Levy B. 2019. Implementation of Basal–Bolus Therapy in Type 2 Diabetes: A Randomized Controlled Trial Comparing Bolus Insulin Delivery Using an Insulin Patch with an Insulin Pen. Diabetes Technology and Therapeutics 21 (5):1-13.
2. Zraick V, Dreon D, Nalk R, Shearer D, Crawford S, Bradford J, Levy B. 2016. Patient User Experience Evaluation of Bolus Patch Insulin Delivery System. Poster presented at the American Diabetes Association's 76th Scientific Sessions. Abstract 995-P. New Orleans, LA, USA

CeQur®

Abundant research shows CeQur Simplicity™ can improve glycemic control

Clinical support:

- Studied in more than 450 patients[1,2,3,4]
- Publications: 4 major papers and 4 original abstracts

Results from Clinical Outcomes Study (n=278):

- Getting patients to goal:
  - A total of **63% of patch users achieved A1C ≤7.0** at week 24[1]
  - A total of **85% of patch users achieved A1C ≤8.0** at week 24
    This number was sustained at the end of the study at week 44[5]

Safety:

- No differences were observed for reported hypoglycemia between groups[1]

Clinical Outcome Study Findings[1]

Mean A1C was reduced to target goal by Week 24



Consistent A1C <7% supports HEDIS Comprehensive Diabetes Care measure

n=278

1. Bergenstal R, Peyrot M, Dreon D, Aroda V, Bailey T, Brazg R, Frias J, Johnson M, Klonoff D, Kruger D, Ramtoola S, Rosenstock J, Serusclat P, Weinstock R, Naik R, Shearer D, Zraick V, Levy B. 2019. Implementation of Basal–Bolus Therapy in Type 2 Diabetes: A Randomized Controlled Trial Comparing Bolus Insulin Delivery Using an Insulin Patch with an Insulin Pen. Diabetes Technology and Therapeutics 21 (5):1-13.
2. Bohannon N, Bergenstal R, Cuddihy R, et al. Comparison of a novel insulin bolus-patch with pen/syringe injection to deliver mealtime insulin for efficacy, preference, and quality of life in adults with diabetes: a randomized, crossover, multicenter study. Diabetes Technol Ther. 2011;13(10):1031-1037.
3. Peyrot M, Dreon D, Zraick V, Cross B, Tan MH. Patient perceptions and preferences for a mealtime insulin delivery patch. Diabetes Ther. 2018;9(1): 297-307.
4. Zraick V, Dreon D, Nalk R, Shearer D, Crawford S, Bradford J, Levy B. 2016. Patient User Experience Evaluation of Bolus Patch Insulin Delivery System. Poster presented at the American Diabetes Association's 76th Scientific Sessions. Abstract 995-P. New Orleans, LA, USA
5. Barry R, Johns D, Rees B. 2019. Transitioning T2DM Patients to Basal-Bolus Insulin Leads to Sustainable A1C Improvement, Diabetes 2019 Jun; 68(Supplement 1)

CeQur®

Use of CeQur Simplicity™ increases time in range

After 24 weeks with CeQur Simplicity, users increased time in range (TIR) by 50%[1]

The International Consensus on Time in Range defines clinical target for TIR ≥70%, which is evidenced to be equivalent to an A1C of ≤7%.[2]

Time in range =48.4%



Baseline

Time in range =74.1%



Week 24

1. Johnson ML, Dreon DM, Levy BL, et al. Comparing Patch versus Pen Bolus Insulin Delivery in Type 2 Diabetes Using Continuous Glucose Monitoring Metrics and Profiles. Paper presented at: 54th Annual Meeting of the European Association for the Study of Diabetes; Oct 1-5, 2018, Berlin, Germany
2. Battelino T, Danne T, et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Tine in Range. 2019. https://doi.org/10.2337/dci19-008

CeQur®

CeQur Simplicity™ delivers high patient and provider satisfaction[1,2,3,4]

Patients using CeQur Simplicity reported:

- Higher overall satisfaction
- Satisfaction with ease of use

HCPs claimed that they:

- **Preferred the patch to pen** to advance T2DM patients from basal to basal/bolus insulin
- Were satisfied with the patch
- Found training the patients to use the patch easy

Patient reported outcomes compared to pen[1]



1. Bergenstal R, Peyrot M, Dreon D, Aroda V, Bailey T, Brazg R, Frias J, Johnson M, Klonoff D, Kruger D, Ramtoola S, Rosenstock J, Serusclat P, Weinstock R, Naik R, Shearer D, Zraick V, Levy B. 2019. Implementation of Basal–Bolus Therapy in Type 2 Diabetes: A Randomized Controlled Trial Comparing Bolus Insulin Delivery Using an Insulin Patch with an Insulin Pen. Diabetes Technology and Therapeutics 21 (5):1-13.
2. Bohannon N, Bergenstal R, Cuddihy R, et al. Comparison of a novel insulin bolus-patch with pen/syringe injection to deliver mealtime insulin for efficacy, preference, and quality of life in adults with diabetes: a randomized, crossover, multicenter study. Diabetes Technol Ther. 2011;13(10):1031-1037.
3. Peyrot M, Dreon D, Zraick V, Cross B, Tan MH. Patient perceptions and preferences for a mealtime insulin delivery patch. Diabetes Ther. 2018;9(1): 297-307.
4. Zraick V, Dreon D, Nalk R, Shearer D, Crawford S, Bradford J, Levy B. 2016. Patient User Experience Evaluation of Bolus Patch Insulin Delivery System. Poster presented at the American Diabetes Association's 76th Scientific Sessions. Abstract 995-P. New Orleans, LA, USA

CeQur®